Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9182485 | 0.82 | — | — | |
| SCHEMBL7155237 | 0.82 | — | — | |
| SCHEMBL8914476 | 0.74 | EGLN1 (0.34) | — | |
| SCHEMBL9185220 | 0.74 | — | — | |
| Glycine SCHEMBL9177787 | 0.74 | GLRA1 (0.31) | — | |
| SCHEMBL19645331 | 0.74 | ALDH1A1 (0.40) | ALDH1A1HSD17B10LMNATDP1FAAH | |
| SCHEMBL9177792 | 0.73 | — | — | |
| SCHEMBL8916896 | 0.73 | — | — | |
| Fluoride SCHEMBL9177797 | 0.73 | EGLN1 (0.33) | — | |
| SCHEMBL621638 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013115813-A1 | WATER SOLUBLE SOLID PHASE PEPTIDE SYNTHESIS | CEM CORPORATION (US) | 2013-08-08 | — | — | WO | disclosed |
| US-20120157563-A1 | WATER SOLUBLE SOLID PHASE PEPTIDE SYNTHESIS | CEM CORPORATION (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120041173-A1 | WATER SOLUBLE SOLID PHASE PEPTIDE SYNTHESIS | CEM CORPORATION (US) | 2012-02-16 | — | — | US | disclosed |
| US-20100056497-A1 | AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056497-A1 | AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2119702-A1 | AMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157563-A1 | WATER SOLUBLE SOLID PHASE PEPTIDE SYNTHESIS | SPAST, DNPEP, SSU72 | ALDH1A1 2427/4885HSD17B10 3462/4885LMNA 1515/4885 |
| US-20120041173-A1 | WATER SOLUBLE SOLID PHASE PEPTIDE SYNTHESIS | ADH1C, SSU72, ADH1A | ALDH1A1 1206/4885HSD17B10 2838/4885LMNA 1372/4885 |
| US-20100056497-A1 | AMIDE DERIVATIVE | REN, AGTR1, AGTR2 | ALDH1A1 348/4885HSD17B10 283/4885LMNA 2412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.